alector.com (ALEC) Price to Earnings Ratio
Alector, Inc. (ALEC) neurodrug development is complicated by international trade conflicts and cross-border logistics issues. The business is currently in a risk zone due to high R&D costs and the anticipation of final trial results for dementia treatments. Price action on GURU.Markets reflects a value of 6.80, while the company strictly adheres to ESG standards by implementing energy-efficient systems and safe bio-waste recycling.
Analytical breakdowns for Alector, Inc.
- price and consensus price forecast:
- market capitalization details:
- book capitalization information:
- debt and solvency information:
Aggregate Debt to Capital Alector, Inc.|ALEC - Long-Term Debt to Equity|Current Liabilities to Capital Alector Therapeutics|ALEC - Company Debts|Debt to Net Assets Ratio Alector, Inc.|ALEC - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Alector|Interim Coverage Ratio alector.com
- business earnings and investment ratios data:
ALEC - Company Net Income|Net Profit Forecast Alector, Inc.|ALEC - P/E Multiple|Projected Price to Earnings Alector Therapeutics|ALEC - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Alector, Inc.|ALEC - Operating profit EBITDA|Net earnings per share (EPS TTM) Alector|ALEC - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months alector.com|ALEC - Earnings growth in current year|Expected net earnings per share growth next year Alector, Inc.
Comprehensive company analysis:alector.com - ALEC
To minimize fundamental risks, investors select assets with proven value relative to generated income. The P/E ratio reflects the market price per share divided by net profit, indicating the investment's payback period. For Alector, Inc. (ALEC), which is scaling robotic antibody screening, this calculation links technology value to actual operational efficiency. Analyzing the company's P/E time series allows for the identification of trend reversal points during its period of technological transformation.
Competing companies
P/E Multiple biogen.com|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Price to Earnings Ratio RGC (Regencell Bioscience Ltd)|P/E Multiple AXSM (Axsome Therapeutics Inc)|ACADIA Corp (ACAD) - Market Cap to Earnings|Xenon Pharmaceuticals - P/E Multiple|vikingtherapeutics.com (VKTX) - Price to Earnings Ratio|SUPN (Supernus) - Price to Earnings Ratio|CPRX: Market Price to Net Income Ratio|Price to Earnings Ratio Denali Therapeutics Inc|Market Cap to Earnings Harmony Corp HRMY|Price to Earnings Ratio Biohaven Ltd. (BHVN)|AMLX (amylyx.com) - Company Value to Net Income|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|Business Payback Period CeriBell EEG CBLL|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|OMER (Omeros Corp) - P/E Multiple|Price to Earnings Ratio Neurogene Inc (NGNE)|Price to Earnings Ratio ACIU (AC Immune Corp)|Business Payback Period Voyager Corp|P/E Multiple NMRA (Neumora Therapeutics)|P/E Multiple scilexholding.com SCLX|TVGN - Price to Earnings Ratio|ACOG: Price to Earnings Ratio|CGTX: P/E Multiple|Market Cap to Earnings Inhibikase Pharma (IKT)|SAVA (Cassava Sciences, Inc.) - P/E Multiple|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|vistagen.com - Price to Earnings Multiple|P/E Multiple OVID (Ovid Therapeutics)|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Earnings|CRVO: Price to Earnings Ratio|ATHE - P/E Multiple|clene.com (CLNN) - Price to Earnings Ratio|PepGen - Company Value to Net Income|Price to Earnings Ratio Jupiter Neurosciences|Market Cap to Earnings Relmada Corp RLMD|P/E Multiple ANVS|P/E Multiple gracetx.com (GRCE)|Price to Earnings Ratio Firefly Neuroscience AIFF|ANEW Medical - Price to Earnings Ratio|NeuroSense Therapeutics, Ltd. - P/E Multiple|Market Cap to Earnings Reviva Pharmaceuticals, Inc.|MTVA: P/E Multiple|Price to Earnings Ratio neuraxis.com|Price to Earnings Ratio HSDT|PASG (Passage Bio Corp) - Market Price to Net Income Ratio|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV - Market Cap to Earnings|Price to Earnings Ratio Athira Pharma, Inc. ATHA|Company Value to Net Income ADXN|ALZN: Price to Earnings Ratio|Company Value to Net Income CYCN (Cyclerion Therapeutics)|PTIX: P/E Multiple|KTTA - Business Payback Period|Price to Earnings Ratio Cortigent Inc|Price to Earnings Multiple ATXI (avenuetx.com)|P/E Multiple BCLI|Price to Earnings Ratio Cara Therapeutics Inc. CARA|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Business Payback Period Eliem Therapeutics, Inc. (ELYM)|Intra-Cellular - P/E Multiple|LBPH - P/E Multiple|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|NKGN (NKGen Biotech Inc) - Price to Earnings Ratio|NRBO (NeuroBo) - P/E Multiple|Market Cap to Earnings Sage Therapeutics Inc SAGE|P/E Multiple SNPX|Price to Earnings Ratio trevena.com TRVN|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|WENA: Price to Earnings Multiple|Cerevel - P/E Multiple
